TOWARD THE GOAL LINE

Updated: September 28, 2008 - 10:47 PM

0
comments
resize text
print
buy reprints

Tweet
share

email
Email share

your name

your email

recipients email

+ add a comment add a comment

Getting stem-cell products to market has been agonizingly slow, but some companies are getting close.

OSIRIS THERAPEUTICS INC.

Headquarters: Columbia, Md.

Business: The company is conducting a Phase III clinical trial of a stem-cell therapy used to treat graft vs. host disease, in which the immune cells from a transplanted bone marrow attack the cells of the recipient.

ATHERSYS INC.

Headquarters: Cleveland

Business: The start-up is developing stem-cell therapies to treat cardiovascular and neurological diseases and cancer.

ALDAGEN INC.

Headquarters: Durham, N.C.

Business: The company just started a Phase III clinical trial of a stem-cell treatment to improve umbilical cord blood transplants for kids with inherited metabolic diseases.